1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dimerix Limited

Dimerix Limited

AASX:DXB
0.21
AUD
+0.00
(-2.38%)
-0.05EPS
123.08MMarket Cap
Mar 01Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
Basic EPS, GAAP
-0.03
-0.03
-0.07
-0.02
-0.03
-0.02
-0.03
-0.03
-0.04
-0.04
-0.04
-0.02
-0.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.11
0.03
0.03
0.04
0.03
0.04
0.01
0.04
0.02
0.03
0.02
-0.02
Tangible Book Value per Share
0.07
0.11
0.03
0.03
0.04
0.03
0.04
0.01
0.04
0.02
0.03
0.02
-0.02
Basic Weighted Avg Shares
18
21
73
87
117
161
175
201
300
326
453
560
600
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6
4
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6,193.35
-572.94
-854.6
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
-5
-2
-3
-3
-4
-6
-10
-14
-17
-13
-30
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-4,190.55
-237.2
-685.32
Working Capital
1
3
2
3
7
4
8
1
14
6
29
50
26
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
3
2
3
7
4
8
1
14
6
18
13
-15
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-36.59
-34.35
-209.36
-72.19
-69.98
-52.19
-75.14
-138.1
-132.03
-135.42
-141.42
-83.97
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
93.46%
158.34%
-210.3%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
32.92%
44.5%
124.98%
Sales/Revenue/Turnover
- -
- -
-22.13%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
6
2026
- -
- -
4

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.04
2025
- -
- -
-0.02
2026
- -
- -
-0.05

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nina Webster
Full Time Employees
15
Sector
Health technology
Industry
Pharmaceuticals: major
Address
425 Smith Street Melbourne VIC Australia 3065
IPO Date
Jul 5, 1989
Website
dimerix.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company specializing in the development and commercialization of pharmaceutical products targeting unmet medical needs in inflammatory diseases, including kidney and respiratory conditions. The company’s core products include DMX-200, a drug candidate in Phase III trials for Focal Segmental Glomerulosclerosis (FSGS) and other kidney diseases, and DMX-700, aimed at treating chronic obstructive pulmonary disease (COPD) and other respiratory disorders. Dimerix leverages its proprietary Receptor Heteromer Investigation Technology (Receptor-HIT) platform, which enables the analysis of receptor interactions to discover and develop novel drug candidates. Founded in 2004 and headquartered in Sydney, Australia, Dimerix operates primarily in Australia with a strategic focus on global markets including the United States and Europe. Recent major developments include the achievement of strategic milestones such as receiving a significant upfront payment from FUSO Pharmaceutical Industries Ltd, continued progress in clinical trials, and the receipt of orphan drug designation for DMX-200 in Japan, reinforcing the company’s commitment to expanding its pipeline and global footprint while advancing its lead candidates toward commercialization. The company maintains a diversified pipeline approach combining innovative new chemical entities and repurposed drugs to mitigate risks and enhance returns, supported by collaborative partnerships and a strategic focus on patent protection and licensing opportunities. Dimerix Limited is listed on the Australian Securities Exchange under ticker DXB.AX.

Company News

Company News APIChatGPT

  • proactiveinvestors.com

    Dimerix licenses DMX-200 rights in Asia to Everest Medicines in deal worth up to A$481 million

  • prnewswire.com

    BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

  • proactiveinvestors.com

    Imugene highlights azer-cel progress as trial patient enters remission

  • proactiveinvestors.com

    Dimerix completes adult dosing in ACTION3 Phase 3 trial as enrolment tops target

  • proactiveinvestors.com

    Imugene reports strong early response rates for azer-cel in lymphoma study

  • proactiveinvestors.com

    Pantoro posts stronger half-year result as Norseman production drives earnings

  • proactiveinvestors.com

    Dimerix US licensing agreement remains intact amid BioMarin–Amicus acquisition

  • prnewswire.com

    DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT